| Number: 201303043 |
Principal Investigator: Lockhart, A. Craig |
| Title: Phase II Study of Levocetirizine in Combination with Capecitabine + Bevacizumab to Overcome Resistance to Anti-angiogenic Therapy in Patients with Refractory Colorectal Cancer |
| Description: The purpose of this research study is to look at how adding a drug called levocetirizine to a standard treatment for colorectal cancer affects how the patient responds to the treatment, as well as looking at the side effects of this type of treatment....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201107017 |
Principal Investigator: Tan, Benjamin |
| Title: A Phase I Dose-Escalation Trial of Biweekly Intraperitoneal Oxaliplatin with Systemic Capecitabine and Bevacizumab Following Cytoreduction in Patients with Peritoneal Carcinomatosis from Appendiceal or Colorectal Cancer |
| Description: The main purpose of this research is to evaluate an intraperitoneal treatment for cancer following a surgical attempt to remove as much or all of the cancer as possible. The goals of this study are to determine the safety and side effects of this treatment, and to learn the maximum tolerated dose (...MORE |
| ___________________________________________________________________________________________________ |
| Number: CALGB 80702 |
Principal Investigator: Tan, Benjamin |
| Title: A Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer |
| Description: In this study, we will evaluate the effects (good and bad) of an oral drug called celecoxib when given in combination with FOLFOX chemotherapy.
...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201212073 |
Principal Investigator: Tan, Benjamin |
| Title: STEAM (Sequencing Triplet with Avastin and Maintenance): Folfoxiri/Bevacizumab Regimens (Concurrent and Sequential) vs. Folfox/Bevacizumab in First-Line Metastatic Colorectal Cancer |
| Description: The purpose of this study is to find out what effects, good or bad, bevacizumab combined with different cancer drugs known as chemotherapy has on the patient and their metastatic colorectal cancer....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201202001 |
Principal Investigator: Zuckerman, Darryl |
| Title: A Phase III Clinical Trial Evaluating TheraSphere in Patients with Metastatic Colorectal Carcinoma of the Liver who have Failed First Line Chemotherapy |
| Description: The purpose of this research study is to examine whether adding treatment with TheraSphere early in the current standard for second-line chemotherapy treatment of metastatic colorectal cancer is better
than the current treatment alone. Better means slowing or stopping the growth of liver tumors
...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201106260 |
Principal Investigator: Birnbaum, Elisa |
| Title: A Phase II, Double-Blind, Placebo-Controlled, Dose Finding Study to Evaluate the Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function in Patients Following Small or Large Bowel Resection with Primary Anastomosis |
| ___________________________________________________________________________________________________ |
| Number: 201011820 |
Principal Investigator: Tan, Benjamin |
| Title: Protocol I4T-MC-JVBB (also known as IMCL CP12 0920) A Randomized, Double-Blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine |
| Description: The purpose of this research study is to see how safe an investigational drug called ramucirumab is and to see how well it helps people with colon cancer.
The primary purpose of this study is to help answer the following research questions:
Can ramucirumab help patients with colon cancer l...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201302001 |
Principal Investigator: Dharmarajan, Sekhar |
| Title: Colorectal Cancer in FAP Patients |
| ___________________________________________________________________________________________________ |
| Number: 201301164 |
Principal Investigator: Liu, Ta-chiang |
| Title: Genetic, molecular, and pathologic analysis of colon cancer |
| ___________________________________________________________________________________________________ |
| Number: 201107368 |
Principal Investigator: Nalbantoglu, ILKe |
| Title: LFAB and Colorectal Cancer |
| ___________________________________________________________________________________________________ |
| Number: 201105072 |
Principal Investigator: Azar, Riad |
| Title: Advanced Colorectal Neoplasia In Patients Under 50 Years: Risk Factors and Outcomes |
| ___________________________________________________________________________________________________ |
| Number: 201212057 |
Principal Investigator: Wise, Paul |
| Title: Cancer risks and mutation spectrum of mismatch repair gene mutations in African American families with Lynch
syndrome |
| ___________________________________________________________________________________________________ |
| Number: 201108327 |
Principal Investigator: Wang-Gillam, Andrea |
| Title: Phase I Study of Erlotinib and Temsirolimus in Resistant Solid Malignancies |
| Description: The purpose of this study is to determine the maximum tolerated dose and side effects of the combination of two drugs, temsirolimus and erlotinib, used to treat solid tumor cancers. Temsirolimus is approved by the Food and Drug Administration (FDA) for treatment of renal cancer and is considered inv...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201107068 |
Principal Investigator: Lockhart, A. Craig |
| Title: Phase I Safety and Pharmacokinetic Study of XRP6258 (Cabazitaxel) In Advanced Solid Tumor Patients with Varying Degrees of Hepatic Impairment |
| Description: The purpose of this study is to determine if Cabazitaxel is a safe treatment for patients with advanced cancers of different types who also have different levels of liver dysfunction. The highest safe dose of cabazitaxel (the maximum tolerated dose, or MTD) that can be given to patients with your le...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201102468 |
Principal Investigator: Lockhart, A. Craig |
| Title: An Open-Label Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 When Administered as a Single Agent in Patients With
Advanced or Metastatic Solid Tumors |
| Description: There are two parts to this research study. The purpose of Part 1 is to find out the highest safe dose of the investigational drug CEP-9722. “Investigational” means that the study drug has not been approved by the United States Food & Drug Administration (F.D.A). Part 2 of the study is to find out m...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201102462 |
Principal Investigator: Lockhart, A. Craig |
| Title: A Phase 1b, Multi-Center, Open Label, Uncontrolled, Serial Cohort, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Daily Oral Doses of ZSTK474 in Subjects with Advanced Solid Malignancies |
| Description: The main purpose of this study is to find out if the drug ZSTK474 is safe in people who have advanced cancers.
ZSTK474 is an investigational (experimental) drug. This means it has not been approved by the Food and Drug Administration (FDA). It is not currently on the market in any country. This stu...MORE |
| ___________________________________________________________________________________________________ |